104 related articles for article (PubMed ID: 8556540)
1. [Enhanced immune functions and antitumor activity of fibroblast-mediated interleukin-2 gene therapy].
Cao XT; Zhang WP; Tao Q
Zhonghua Yi Xue Za Zhi; 1995 Sep; 75(9):521-4, 573. PubMed ID: 8556540
[TBL] [Abstract][Full Text] [Related]
2. [Experimental study on the treatment of human hepatocellular carcinoma by fibroblast-mediated human IFN-alpha gene therapy in combination with adoptive chemoimmunotherapy].
Wang J; Cao X; Kong X
Zhonghua Zhong Liu Za Zhi; 1995 Jul; 17(4):266-70. PubMed ID: 7587892
[TBL] [Abstract][Full Text] [Related]
3. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of interleukin-18 gene-modified hepatocyte cell line on implanted liver carcinoma.
Leng J; Zhang L; Yao H; Cao X
Chin Med J (Engl); 2003 Oct; 116(10):1475-9. PubMed ID: 14570604
[TBL] [Abstract][Full Text] [Related]
5. [Antitumor effect of interleukin-2 gene-transfected tumor vaccine in combination with interleukin-6 gene-transfected tumor vaccine].
Cao X; Zhang W; Tao Q
Zhonghua Yi Xue Za Zhi; 1995 Oct; 75(10):602-5, 639. PubMed ID: 8697075
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine neoplasms induce tumor-specific immune responses that prolong the lives of tumor-bearing mice.
Sun T; Kim TS; Waltz MR; Cohen EP
Cancer Gene Ther; 1995 Sep; 2(3):183-90. PubMed ID: 8528961
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
[TBL] [Abstract][Full Text] [Related]
8. Regional treatment of hepatic micrometastasis by adenovirus vector-mediated delivery of interleukin-2 and interleukin-12 cDNAs to the hepatic parenchyma.
Hirschowitz EA; Naama HA; Evoy D; Lieberman MD; Daly J; Crystal RG
Cancer Gene Ther; 1999; 6(6):491-8. PubMed ID: 10608345
[TBL] [Abstract][Full Text] [Related]
9. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma.
Hu P; Hu HD; Chen M; Peng ML; Tang L; Tang KF; Matsui M; Belladonna ML; Yoshimoto T; Zhang DZ; Xiang R; Ren H
Mol Immunol; 2009 May; 46(8-9):1654-62. PubMed ID: 19299021
[TBL] [Abstract][Full Text] [Related]
10. Soluble glucan and lymphokine-activated killer (LAK) cells in the therapy of experimental hepatic metastases.
Sherwood ER; Williams DL; McNamee RB; Jones EL; Browder IW; Di Luzio NR
J Biol Response Mod; 1988 Apr; 7(2):185-98. PubMed ID: 3283299
[TBL] [Abstract][Full Text] [Related]
11. [The anti-tumor efficacy of human recombinant interleukin-2 (rIL-2) in vivo].
Wang C; Chai L; Zhu G
Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):27-9. PubMed ID: 7656782
[TBL] [Abstract][Full Text] [Related]
12. Preliminary study on mouse interleukin-21 application in tumor gene therapy.
Dou J; Chen G; Wang J; Zhao F; Chen J; Fang X; Tang Q; Chu L
Cell Mol Immunol; 2004 Dec; 1(6):461-6. PubMed ID: 16293216
[TBL] [Abstract][Full Text] [Related]
13. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of hepatocellular carcinoma by transfecting interleukin-12 and interleukin-2 fusion gene intrasplenically, an experimental study].
Yang JH; Fan RF; Qian QJ; You TG; Xue HB; Su CQ; Cao HF; Wu MC
Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):740-3. PubMed ID: 12899748
[TBL] [Abstract][Full Text] [Related]
17. Efficient inducation of local and systemic antitumor immune response by liposome-mediated intratumoral co-transfer of interleukin-2 gene and interleukin-6 gene.
Cao X; Wang Q; Ju DW; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):191-200. PubMed ID: 10464706
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.
Wang Q; Yu H; Ju DW; He L; Pan JP; Xia DJ; Zhang LH; Cao X
Gene Ther; 2001 Apr; 8(7):542-50. PubMed ID: 11319621
[TBL] [Abstract][Full Text] [Related]
19. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma.
Ju DW; Tao Q; Cheng DS; Zhang W; Zhang M; Hamada H; Cao X
Gene Ther; 2000 Feb; 7(4):329-38. PubMed ID: 10694814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]